{
    "Trade/Device Name(s)": [
        "BD BBL Sensi-Disc Lefamulin 20 \u03bcg (LMU-20)"
    ],
    "Submitter Information": "Becton, Dickinson and Company",
    "510(k) Number": "K230651",
    "Predicate Device Reference 510(k) Number(s)": [
        "K192326"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "JTN"
    ],
    "Summary Letter Date": "March 8, 2023",
    "Summary Letter Received Date": "March 9, 2023",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.1620"
    ],
    "Regulation Name(s)": [
        "Antimicrobial Susceptibility Test Disc"
    ],
    "Analyte Class(es)": [
        "microbiology"
    ],
    "Analyte(s)": [
        "Lefamulin"
    ],
    "Specimen Type(s)": [
        "Pure culture isolates of bacteria"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "BD BBL Sensi-Disc Dispenser"
    ],
    "Method(s)/Technology(ies)": [
        "Agar diffusion",
        "Disk diffusion susceptibility test",
        "Kirby-Bauer"
    ],
    "Methodologies": [
        "Semi-quantitative agar diffusion",
        "Zone diameter measurement"
    ],
    "Submission Type(s)": [
        "Reagent",
        "Disc",
        "Cartridge"
    ],
    "Document Summary": "FDA 510(k) summary for BD BBL Sensi-Disc Lefamulin 20 \u03bcg (LMU-20) for in vitro antimicrobial susceptibility testing of bacterial isolates by disk diffusion.",
    "Indications for Use Summary": "Used in semi-quantitative agar diffusion tests to determine bacterial susceptibility to Lefamulin for Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible), and Haemophilus influenzae.",
    "fda_folder": "Microbiology"
}